Use the collections feature with a free QxMD account.
Use Read by QxMD to access full text via your institution or open access sources.
Read also provides personalized recommendations to keep you up to date in your field.
Existing User
Sign InNew to Read
Sign Up
Collections
Most Read Papers - Pediatric H...
Most Read Papers - Pediatric Hematology/Oncology
• Most Read Papers - Pediatric Hematology/Oncology
#1
JOURNAL ARTICLE
Ursula La Rocca, Maria P Perrone, Alfonso Piciocchi, Walter Barberi, Paola Gesuiti, Luca Laurenti, Paola Cinti, Maria Gozzer, Manhaz Shafii Bafti, Daniela Carmini, Nadia Cinelli, Claudio Cavallari, Gianluca Giovannetti, Roberto Ricci, Gabriella Girelli, Robin Foà, Maurizio Martelli, Serelina Coluzzi, Anna P Iori
BACKGROUND: In the setting of mismatched-hematopoietic stem cells transplantation, the detection of antibodies directed against donor-specific HLA allele(s) or antigen(s) (DSA) represents a barrier for engraftment. It is thus necessary to plan an immunosuppressive strategy, or to select an alternative donor. This prospective study aimed at evaluating the efficacy of our strategy for testing DSAs and the efficacy of the desensitization strategy (DS) employed between November 2017 and November 2020...
March 2024: Blood Transfusion
#2
JOURNAL ARTICLE
Romy Elise van Weelderen, Christine J Harrison, Kim Klein, Yilin Jiang, Jonas Abrahamsson, Todd Alonzo, Richard Aplenc, Nira Arad-Cohen, Emmanuelle Bart-Delabesse, Barbara Buldini, Barbara De Moerloose, Michael N Dworzak, Sarah Elitzur, José M Fernández Navarro, Alan S Gamis, Robert B Gerbing, Bianca F Goemans, Hester A de Groot-Kruseman, Erin M Guest, Shau Yin Ha, Henrik Hasle, Charikleia Kelaidi, Helene Lapillonne, Guy Leverger, Franco Locatelli, Takako Miyamura, Ulrika Noren-Nystrom, Sophia Polychronopoulou, Mareike Rasche, Jeffrey E Rubnitz, Jan Stary, Anne Tierens, Daisuke Tomizawa, Michel C Zwaan, Gertjan J L Kaspers
Comprehensive international consensus on cytogenetic risk-group stratification of KMT2A-rearranged (KMT2A-r) pediatric acute myeloid leukemia (AML) is lacking. This retrospective (2005-2016) International Berlin-Frankfurt-Münster Study Group study on 1,256 children with KMT2A-r AML aimed to validate the prognostic value of established recurring KMT2A fusions and additional cytogenetic aberrations (ACAs), and secondly, to define additional, recurring KMT2A fusions and ACAs, evaluating their prognostic relevance...
April 15, 2024: Blood Advances
#3
JOURNAL ARTICLE
Juliette Renaud, Bianca F Goemans, Franco Locatelli, Martina Pigazzi, Shelagh Redmond, Claudia E Kuehni, Alice Destaillats, Todd A Alonzo, Robert B Gerbing, Alan Gamis, Richard Aplenc, Raffaele Renella, Todd Cooper, Francesco Ceppi
BACKGROUND: Myeloid neoplasms account for 50% of cases of pediatric leukemias in infants. Approximately 25%-50% of patients with newborn leukemia have cutaneous extramedullary disease (EMD). In less than 10% of patients, aleukemic leukemia cutis or isolated extramedullary disease with cutaneous involvement (cEMD) occurs when skin lesions appear prior to bone marrow involvement and systemic symptoms. Interestingly, in acute myeloid leukemia with cutaneous EMD (AML-cEMD) and cEMD, spontaneous remissions have been reported...
April 14, 2024: Pediatric Blood & Cancer
#4
JOURNAL ARTICLE
Juan Carlos Núñez-Enríquez, Rubí Romo-Rodríguez, Pedro Gaspar-Mendoza, Gabriela Zamora-Herrera, Lizeth Torres-Pineda, Jiovanni Amador-Cardoso, Jebea A López-Blanco, Laura Alfaro-Hernández, Lucero López-García, Arely Rosas-Cruz, Dulce Rosario Alberto-Aguilar, César Omar Trejo-Pichardo, Dalia Ramírez-Ramírez, Astin Cruz-Maza, Janet Flores-Lujano, Nuria Luna-Silva, Angélica Martínez-Martell, Karina Martínez-Jose, Anabel Ramírez-Ramírez, Juan Carlos Solis-Poblano, Patricia Zagoya-Martínez, Vanessa Terán-Cerqueda, Andrea Huerta-Moreno, Álvaro Montiel-Jarquín, Miguel Garrido-Hernández, Raquel Hernández-Ramos, Daniela Olvera-Caraza, Cynthia Shanat Cruz-Medina, Enoch Alvarez-Rodríguez, Lénica Anahí Chávez-Aguilar, Wilfrido Herrera-Olivares, Brianda García-Hidalgo, Lena Sarahí Cano-Cuapio, Claudia Guevara-Espejel, Gerardo Juárez-Avendaño, Juan Carlos Balandrán, Ma Del Rocío Baños-Lara, Mariana Cárdenas-González, Elena R Álvarez-Buylla, Sonia Mayra Pérez-Tapia, Diana Casique-Aguirre, Rosana Pelayo
The main objective of the National Project for Research and Incidence of Childhood Leukemias is to reduce early mortality rates for these neoplasms in the vulnerable regions of Mexico. This project was conducted in the states of Oaxaca, Puebla, and Tlaxcala. A key strategy of the project is the implementation of an effective roadmap to ensure that leukemia patients are the target of maximum benefit of interdisciplinary collaboration between researchers, clinicians, surveyors, and laboratories. This strategy guarantees the comprehensive management of diagnosis and follow-up samples of pediatric patients with leukemia, centralizing, managing, and analyzing the information collected...
2024: Frontiers in Oncology
#5
REVIEW
Francesca A M Kinsella, Maria A L Maroto, Justin Loke, Charles Craddock
Allogeneic stem cell transplantation is a centrally important curative strategy in adults with acute myeloid leukaemia; however, relapse occurs in a significant proportion of patients and remains the leading cause of treatment failure. The prognosis for patients who relapse post-transplant remains poor, and the development of new strategies with the ability to reduce disease recurrence without increasing transplant toxicity remains a priority. In this review, within the context of our understanding of disease biology and the graft-versus-leukaemia (GVL) effect, we will discuss established, evolving and novel approaches for increasing remission rates, decreasing measurable residual disease pretransplant, future methods to augment the GVL effect and the opportunities for post-transplant maintenance...
April 11, 2024: British Journal of Haematology
#6
REVIEW
Zhen-Yu Xiong, Yao-Jia Shen, Shi-Zhong Zhang, Hong-Hu Zhu
Philadelphia chromosome-positive acute lymphoblastic leukemia (PH + ALL) is the most common cytogenetic abnormality of B-ALL in adults and is associated with poor prognosis. Previously, the only curative treatment option in PH + ALL was allogeneic hematopoietic stem cell transplantation (Allo-HSCT). Since 2000, targeted therapy combined with chemotherapy, represented by the tyrosine kinase inhibitor Imatinib, has become the first-line treatment for PH + ALL. Currently, the remission rate and survival rate of Imatinib are superior to those of simple chemotherapy, and it can also improve the efficacy of transplantation...
December 2024: Hematology (Amsterdam, Netherlands)
#7
JOURNAL ARTICLE
Emma Kroeze, Ingram Iaccarino, Michelle M Kleisman, Mayukh Mondal, Thomas Beder, Mouhamad Khouja, Marc P Höppner, Marijn A Scheijde-Vermeulen, Lennart A Kester, Monika Brüggemann, Claudia D Baldus, Gunnar Cario, Reno S Bladergroen, Nathalie Garnier, Andishe Attarbaschi, Jaime Verdu-Amorós, Rosemary Sutton, Elizabeth A Macintyre, Kenneth Scholten, Laura Arias Padilla, Birgit Burkhardt, Auke Beishuizen, Monique L den Boer, Roland P Kuiper, Jan L C Loeffen, Judith M Boer, Wolfram Klapper
Pediatric B-cell precursor (BCP) lymphoblastic malignancies are neoplasms with manifestation either in bone marrow/blood (BCP acute lymphoblastic leukemia, BCP-ALL) or less common in extramedullary tissue (BCP lymphoblastic lymphoma, BCP-LBL). Although both presentations are similar in morphology and immunophenotype, molecular studies are virtually restricted to BCP-ALL so far. The lack of molecular studies on BCP-LBL is due to its rarity and the restriction to small, mostly formalin-fixed paraffin embedded (FFPE) tissues...
April 8, 2024: Blood
#8
JOURNAL ARTICLE
Babe Westlake, Jeffrey Brown, Jacqueline Hart, Cameron Skiby, Kevin Jones, John Groundland
INTRODUCTION: Bone sarcomas are known to have a predilection for pulmonary metastasis. Surveillance protocols are thus focused on periodic chest imaging, typically with CT scan. Pulmonary nodules can be easily identified with this modality, but smaller nodules are not readily biopsied and may not represent metastatic disease. These are called indeterminate. The natural history of indeterminate nodules in a bone sarcoma population and factors associated with progression to true metastatic disease are not clearly defined...
2024: Sarcoma
#9
JOURNAL ARTICLE
Wenxin Zhang, Junren Dai, Guixue Hou, Hao Liu, Shanliang Zheng, Xingwen Wang, Qingyu Lin, Yi Zhang, Minqiao Lu, Yafan Gong, Zhiyuan Xiang, Yan Yu, Ying Hu
Ferroptosis is a non-apoptotic form of regulated cell death. Glutathione (GSH) peroxidase 4 (GPX4) and GSH-independent ferroptosis suppressor protein 1 (FSP1) have been identified as major defenses. Here, we uncover a protective mechanism mediated by GSH S-transferase P1 (GSTP1) by monitoring proteinomic dynamics during ferroptosis. Dramatic downregulation of GSTP1 is caused by SMURF2-mediated GSTP1 ubiquitination and degradation at early stages of ferroptosis. Intriguingly, GSTP1 acts in GPX4- and FSP1-independent manners by catalyzing GSH conjugation of 4-hydroxynonenal and detoxifying lipid hydroperoxides via selenium-independent GSH peroxidase activity...
December 7, 2023: Molecular Cell
#10
REVIEW
Gordan M Vujanić, William Mifsud
Anaplasia in Wilms tumor is recognized as the most important prognostically unfavorable histological feature. It is subtyped as focal anaplastic Wilms tumor (FAWT) and diffuse anaplastic Wilms tumor (DAWT). Outcomes of patients with DAWT remain poor in patients with stage III and IV tumors. Important issues relevant to anaplasia in Wilms tumor, including prevalence, treatment, outcomes, biomarkers, anaplasia, and chemotherapy, and the concept of tumor aggressiveness, are reviewed and discussed here. We also consider the differences in clinical approaches to anaplasia in Wilms tumor between the two major renal tumor clinical research groups: the International Society of Paediatric Oncology (SIOP) Renal Tumour Study Group and the Children's Oncology Group (COG) Renal Tumor Group...
April 11, 2024: Pediatric Blood & Cancer
#11
REVIEW
Euan Ballantyne, Connor Evans, Lucy Shepherd, Helen Fulbright, Sara Wakeling, Bob Phillips, Jessica E Morgan
Approximately one third of children with rhabdomyosarcoma relapse or have refractory disease. Treatment approaches include a combination of systemic therapies and local therapies, directed at tumour site(s). This review was conducted to evaluate the effectiveness and safety of the combination of surgery and brachytherapy as local therapy for treating children and young people with relapsed/refractory rhabdomyosarcoma. This review identified studies based on a previous systematic review looking at the treatments for children and young people under 18 years old with relapsed/refractory rhabdomyosarcoma...
April 2, 2024: Pediatric Blood & Cancer
#12
MULTICENTER STUDY
Hugo R Paganini, Clarisa Aguirre, Gabriela Puppa, Cecilia Garbini, Javier Ruiz Guiñazú, Gabriela Ensinck, Claudia Vrátnica, Luis Flynn, Marisa Iacono, Pedro Zubizarreta
BACKGROUND: Many studies have succeeded in identifying a subset of children with febrile neutropenia (FN) who are at lower risk of infectious complications and eventual death. Conversely, to the authors' knowledge, no scoring system has been published to date with which to assess the risk of mortality for the whole group of children with neutropenia and fever. METHODS: Between March 2000 and July 2004, 1520 episodes of FN in 981 children were included in a multicentric prospective study to evaluate a scoring system that was designed to identify high mortality risk at the onset of an FN episode in children with cancer...
June 15, 2007: Cancer
#13
JOURNAL ARTICLE
Will Lester, Clare Bent, Raza Alikhan, Laura Roberts, Tim Gordon-Walker, Sarah Trenfield, Richard White, Colm Forde, Deepa J Arachchillage
No abstract text is available yet for this article.
March 22, 2024: British Journal of Haematology
#14
JOURNAL ARTICLE
Sean Platton, Peter Baker, Annette Bowyer, Catriona Keenan, Caroline Lawrence, Will Lester, Anne Riddell, Megan Sutherland
No abstract text is available yet for this article.
March 26, 2024: British Journal of Haematology
#15
JOURNAL ARTICLE
Francesco Negrini, Alessandro de Sire, Elisa Andrenelli, Stefano G Lazzarini, Michele Patrini, Maria G Ceravolo
INTRODUCTION: This living systematic review presents the monthly update of the second edition of the rapid living systematic review 2020 conducted by Cochrane Rehabilitation REH-COVER Action Steering Committee. The aim of this study was to update the monthly COVID-19 and rehabilitation literature research up to October 31st , 2020. EVIDENCE ACQUISITION: Methodology described in the second edition of the rapid living systematic review 2020 conducted by Cochrane Rehabilitation REH-COVER action was applied...
February 2021: European Journal of Physical and Rehabilitation Medicine
#16
JOURNAL ARTICLE
Renato Gualtieri, Fanette Bernard, Klara Posfay-Barbe, Geraldine Blanchard-Rohner
No abstract text is available yet for this article.
March 13, 2024: Journal of Pediatric Hematology/oncology
#17
JOURNAL ARTICLE
Signe Holst Søegaard, Mie Mølgaard Andersen, Klaus Rostgaard, Olafur Birgir Davidsson, Sjurdur Frodi Olsen, Kjeld Schmiegelow, Henrik Hjalgrim
IMPORTANCE: Breastfeeding has been suggested to protect against childhood cancers, particularly acute lymphoblastic leukemia (ALL). However, the evidence stems from case-control studies alone. OBJECTIVE: To investigate whether longer duration of exclusive breastfeeding is associated with decreased risk of childhood ALL and other childhood cancers. DESIGN, SETTING, AND PARTICIPANTS: This population-based cohort study used administrative data on exclusive breastfeeding duration from the Danish National Child Health Register...
March 4, 2024: JAMA Network Open
#18
REVIEW
Layla Van Doren, Marlene Steinheiser, Kristen Boykin, Kristine J Taylor, Monica Menendez, Michael Auerbach
Intravenous iron has become an essential component for the treatment of iron deficiency and iron deficiency anemia. Individuals administering Intravenous iron should have knowledge in intravenous iron administration, including a pre-infusion assessment to evaluate infusion reaction risks, pre- and post-infusion monitoring, identification of and management of infusion reactions, accurate documentation of these reactions, laboratory monitoring and recognition and management of treatment-emergent hypophosphatemia...
January 29, 2024: American Journal of Hematology
#19
JOURNAL ARTICLE
Julia Chisholm, Henry Mandeville, Madeleine Adams, Veronique Minard-Collin, Timothy Rogers, Anna Kelsey, Janet Shipley, Rick R van Rijn, Isabelle de Vries, Roelof van Ewijk, Bart de Keizer, Susanne A Gatz, Michela Casanova, Lisa Lyngsie Hjalgrim, Charlotte Firth, Keith Wheatley, Pamela Kearns, Wenyu Liu, Amanda Kirkham, Helen Rees, Gianni Bisogno, Ajla Wasti, Sara Wakeling, Delphine Heenen, Deborah A Tweddle, Johannes H M Merks, Meriel Jenney
The Frontline and Relapsed Rhabdomyosarcoma (FaR-RMS) clinical trial is an overarching, multinational study for children and adults with rhabdomyosarcoma (RMS). The trial, developed by the European Soft Tissue Sarcoma Study Group (EpSSG), incorporates multiple different research questions within a multistage design with a focus on (i) novel regimens for poor prognostic subgroups, (ii) optimal duration of maintenance chemotherapy, and (iii) optimal use of radiotherapy for local control and widespread metastatic disease...
February 29, 2024: Cancers
#20
Yanzhi Song, Zhanxiang Liu, Qi Wang, Kong Gao, Tong Wu
INTRODUCTION: Patients with relapsed/refractory (r/r) acute T-lymphoblastic leukemia (T-ALL) have a poor prognosis. We developed donor CD7 chimeric antigen receptor T (CAR-T) cells to salvage r/r T-ALL patients and obtained encouraging results. Patients who had not received allogeneic (allo-) hematopoietic stem cell transplantation (HSCT) before CAR-T therapy would develop pancytopenia and immunodeficiency for a long period after CD7 CAR-T therapy; therefore, allo-HSCT is needed in these patients...
2024: Frontiers in Immunology
Make the most of Read.
Download the mobile app.
Download the mobile app.
Fetching more papers... 
